Study Summary
The purpose of this Phase 1/2a trial is to evaluate the safety, tolerability, and preliminary efficacy of PBGENE-DMD in patients with DMD harboring mutations amenable to excision of exons 45-55. Given the limitations of existing therapeutic strategies, PBGENE-DMD represents a novel, innovative approach with the potential for a one-time, durable correction of the underlying genetic defect in the largest molecular subset of patients with DMD.
Want to learn more about this trial?
Request More InfoInterventions
PBGENE-DMD (IV)BIOLOGICAL
Participants will receive a single dose of PBGENE-DMD
Study Locations
No locations listed.